12 The identification of molecular subsets with higher rates of genomic amplification of targetable receptor-associated tyrosine kinase pathways, along with higher rates of PIK3CA kinase mutation, ...

US FDA grants priority review status to Bayer’s sevabertinib to treat patients with HER2-mutant non-small cell lung cancer: Berlin Friday, May 30, 2025, 16:00 Hrs [IST] Bayer an ...

The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Engagement of integrin receptors ... tyrosine kinases and small GTPases of the Rho family. In this review, we consider the role of the focal complex associated protein tyrosine kinase, Focal ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's new drug application (NDA) and granted Priority Review designation for the investigational compound ...

Imatinib potently inhibits a select set of tyrosine kinases at submicromolar concentrations, including the platelet-derived growth factor receptor ... of tyrosine kinase pathways represents ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono"), today announced that the results from the open label Phase 2 PROSPECT Study of tirabrutinib is to be ...

Detailed price information for Eyepoint Pharmaceuticals Inc (EYPT-Q) from The Globe and Mail including charting and trades.

A Cancer Gene Therapy study reveals that MEOX2 promotes lung cancer progression while SMARCB1 acts as a tumor suppressor, ...